RxDoctor Payments Data

Emmanuel Pelayo

Adult Health · New York, NYNPI 1770992836

Payments from drug & device makers

$982in general payments, 2019–2025

Across 25 payments — averaging $39.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$248
  • Lilly USA, LLC$195
  • E.r. Squibb & Sons, L.L.C.$122
  • Eisai Inc.$116
  • Scilex Pharmaceuticals Inc.$68
  • Tempus AI, Inc$47
  • plus $187 from 8 others

What the payments were for

  • Food & beverage$982100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$982 in reported general payments places this provider in the 65th percentile of 3,828 adult health providers in New York.

See all adult health providers in New York

Medicare billing

Part B allowed, 2024
$8,850
Medicare patients
62
Services billed
126

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
WegovySemaglutide14$20,509
MounjaroTirzepatide12$12,231
Atorvastatin Calcium61$610
Rosuvastatin Calcium32$388
Tamsulosin Hcl21$372
Montelukast Sodium24$189
Amlodipine Besylate29$169
Omeprazole14$154
Fluticasone Propionate11$153
Metformin Hcl30$150
Gabapentin13$135
Losartan Potassium26$120
Metoprolol Tartrate14$48

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskWegovy$248$20,50914 claims
Lilly USA, LLCMounjaro$195$12,23112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 3,828 adult health providers in New York.

Other adult health in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →